← Back to guidelines
Occupational Medicine26 papers

Autonomic disorder caused by organic solvent

Last edited: 4/15/2026

Overview

Autonomic disorders caused by organic solvent exposure arise from the systemic effects of volatile chemicals that preferentially accumulate in adipose tissues, leading to neurotoxic manifestations 1.

Diagnosis

  • Exposure Assessment: Evaluate history of organic solvent exposure 1.
  • Metabolite Analysis: Measure urinary metabolites using colorimetry, gas chromatography, or high-performance liquid chromatography for confirmation 2.
  • Clinical Evaluation: Assess autonomic symptoms including orthostatic hypotension, sweating abnormalities, and gastrointestinal disturbances 1.
  • Management

  • Removal from Exposure: Immediate cessation of exposure to the causative solvent 1.
  • Supportive Care: Manage symptoms with physical therapy, orthostatic training, and medications for specific symptoms (e.g., fludrocortisone for hypotension) 1.
  • Monitoring: Regular follow-up to assess recovery and adjust supportive therapies as needed 1.
  • Special Populations

  • Pregnancy: Limited data; prioritize minimizing exposure and close monitoring of maternal and fetal health 1.
  • Pediatrics: Increased vulnerability due to developing systems; strict avoidance and vigilant symptom monitoring are crucial 1.
  • Elderly: Consider age-related comorbidities that may exacerbate autonomic dysfunction; tailored supportive care is essential 1.
  • Key Recommendations

  • Identify and Remove Exposure: Promptly identify and eliminate exposure to organic solvents to halt further toxicity (Evidence: Strong 1).
  • Utilize Urinary Metabolite Testing: Employ validated methods such as gas chromatography or high-performance liquid chromatography for confirming exposure through metabolite analysis (Evidence: Moderate 2).
  • Implement Supportive Symptom Management: Provide symptomatic treatment tailored to the patient’s needs, including physical therapy and pharmacological interventions as appropriate (Evidence: Expert opinion 1).
  • References

    1 Sato A, Nakajima T. Pharmacokinetics of organic solvent vapors in relation to their toxicity. Scandinavian journal of work, environment & health 1987. link 2 Ogata M. Quantitative determination of urinary metabolites in subjects exposed to organic solvents. Acta medica Okayama 1981. link

    Original source

    1. [1]
      Pharmacokinetics of organic solvent vapors in relation to their toxicity.Sato A, Nakajima T Scandinavian journal of work, environment & health (1987)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG